Status: Recruiting
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Participants needed: 220
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: Circle PharmaUpdated: Sep 15, 2025Locations: 10
Eligibility criteria
Part 1a Dose Escalation and Part 1b New Formulation Dose Escalation/Pilot Food E... [+17]
Targeted therapy ≤ eight days or 5× the terminal phase elimination half-lives, w... [+76]